Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease

Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2015, Pages 241-250

  Tortorici, Michael A ^a   Cutler, David L ^b   Hazra, Anasuya ^c   Nolin, Thomas D ^d   Rowland Yeo, Karen ^e   Venkatakrishnan, Karthik ^f  

^a CSL Behring LLC   (United States)

^b Merck and CoUpper Whales   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e CERTARA   (United States)

^f TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

chronic kidney disease; dosing recommendations; pharmacokinetics; physiologically based pharmacokinetics; renal safety

Indexed keywords

ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG RESEARCH; DRUG SAFETY; HUMAN; ONCOLOGY; PHARMACOKINETICS; RISK BENEFIT ANALYSIS; STUDY DESIGN; ANIMAL; BIOLOGICAL MODEL; DOSE CALCULATION; DRUG INTERACTION; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; URINARY EXCRETION;

DRUG;

ANIMALS; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; HUMANS; KIDNEY; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RENAL ELIMINATION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84952644542     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.444     Document Type: Article

References (62)

1. KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Working Group KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic. Kid Int Suppl. 2013; 3 (1): 1-150.
2. Naud J, Nolin TD, Leblond FA, Pichette V,. Current understanding of drug disposition in kidney disease. J Clin Pharmacol. 2012; 52 (suppl 1): 10S-22S.
3. Yeung CK, Shen DD, Thummel K, Himmelfarb J,. Effect of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kid Int. 2014; 85 (3): 522-528.
4. US Food Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling 1998. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf.
5. US Food Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf.
6. European Medicines Agency. Note for guidance on the evaluation of pharmacokinetics of medicinal products in patients with impaired kidney function 2004. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003123.pdf.
7. European Medicines Agency. 2014 guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/02/WC500162133.pdf.
8. Stevens LA, Coresh J, Greene T, Levy AS,. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354 (23): 2473-2483.
9. Nyman HA, Dowling TC, Hudson JQ, et al., Comparative evaluation of the Cockcroft-Gault equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the nephrology practice and research network of the American College of Clinical Pharmacy. Pharmacotherapy. 2011; 31 (11): 1130-1144.
10. Tortorici MA, Cutler D, Zhang L, Pfister M,. Design, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney function. J Clin Pharmacol. 2012; 52 (suppl 1): 109S-118S.
11. Tortorici MA, Nolin TD,. Kidney function assessment & its role in drug development, review, and utilization. Exp Rev Clin Pharmacol. 2014; 7 (4): 523-532.
12. Froissart M, Rossert J, Jacquot C, et al., Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005; 16 (3): 763-773.
13. Lalonde RL, Wagner JA,. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Clin Pharmacol Ther. 2009; 86 (5): 557-561.
14. Momper JD, Venkataramanan R, Nolin TD,. Nonrenal drug clearance in CKD: searching the path less traveled. Adv Chronic Kid Dis. 2010; 17: 384-391.
15. Wargo KA, Eiland EH 3rd, Hamm W,. Comparison of the modification of diet in renal disease and Cockcroft-Gault equations for antimicrobial dosage adjustments. Ann Pharmacother. 2006; 40 (7-8): 1248-1253.
16. Goulin-Thibault I, Pautas E, Mahe I, et al., Is Modification of Diet in Renal Disease formula similar to Cockcroft-Gault formula to assess renal function in elderly hospitalized patients treated with low-molecular-weight-heparin. J Gerontol A Biol Scie Med Sci. 2007; 62 (11): 1300-1305.
17. Hermsen ED, Maiefski M, Florescu MC, et al., Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials. Pharmacotherapy. 2009; 29 (6): 649-655.
18. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 ((2 suppl 1)): S1-S266.
19. Rahman A, White RM,. Cytotoxic anticancer agents and renal impairment study: the challenge remains. J Clin Oncol. 2006; 24 (4): 533-536.
20. Mita AC, Sweened CJ, Baker SD, et al., Phase 1 and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006; 24 (4): 552-562.
21. Superfin D, Iannucci AA, Davies AM,. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist. 2007; 12 (9): 1070-1083.
22. Takimoto CH, Remick SC, Sharma S, et al., Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Work Group Study. J Clin Oncol. 2003; 21 (14): 2664-2672.
23. Takimoto CH, Graham MA, Lockwood G, et al., Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007; 13: 4832-4839.
24. Gibbons J, Egorin MJ, Ramanathan RK, et al., Phase 1 and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study of the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008; 26 (4): 570-576.
25. Leal TB, Remick SC, Takimoto CH, et al., Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Work Group Study. Cancer Chemother Pharmacol. 2011; 68 (6): 1439-1447.
26. Ibrahim S, Honig P, Huang SM, Gillespie W, Lesko LJ, Williams RL,. Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol. 2000; 40 (1): 31-38.
27. Zhang L, Xu N, Xiao S, et al., J Clin Pharmacol. 2012; 52 (suppl 1): 79S-90S.
28. Huang SM, Lesko LJ, Williams RL,. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol. 1999; 39 (10): 1006-1014.
29. Cymbalta USPI. http://pi.lilly.com/us/cymbalta-pi.pdf. Published 2004.
30. Lobo ED, Quinlan T, O'Brien L, Knadler MP, Heathman M,. Population pharmacokinetics of orally administered duloxetine in patients. Clin Pharmacokinet. 2009; 48 (3): 189-197.
31. Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH,. A review of the clinical pharmacokinetics and pharmacodynamics of varenecline for smoking cessation. Clin Pharmacokinet. 2010; 49 (12): 799-816.
32. Lehr T, Haertter S, Liesenfeld KH, et al., Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012; 52 (9): 1373-1378.
33. Hariharan S, Madabushi R,. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol. 2012: 119S-125S.
34. van der Walt JS, Hong Y, Zhang L, et al., A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-o-glucuronide in renal or hepatic impairment. CPT Pharmacometrics Syst Pharmacol. 2013; 2: e42.
35. Duong JK, Kumar SS, Kirkpatrick CM, et al., Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet. 2013; 52 (5): 373-384.
36. Gibson GG, Rostami-Hodjegan A,. Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). Xenobiotica. 2007; 37 (10-11): 1013-1014.
37. Rowland-Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A,. Modeling and predicting drug pharmacokinetics in renal impairment. Exp Rev Clin Pharmacol. 2011; 4 (2): 261-274.
38. Zhao P, Vieira M, Grillo JA, et al., Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012: 52 (suppl 1) 91S-108S.
39. Grillo JA, Zhao P, Bullock J, Booth BP,. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos. 2012: 33 99-110.
40. Rowland Yeo, Jamei K, Yang M, Tucker J, Rostami-Hodjegan GT,. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci. 2010; 39: 298-309.
41. Hsu CY, McCulloch CE, Curhan GC,. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002; 13 (11): 2783-2786.
42. Hsu CY,. Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens. 2012; 11 (3): 337-341.
43. National Health and Nutrition Examination Survey 1999-2004. http://www.cdc.gov/nchs/nhanes.htm.
44. Stenvinkel P, Heimburger O, Paultre F, et al., Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kid Int. 1999; 55:(5): 1899-1911.
45. Aparicio M, Chauveau P, De Precigout V, Bouchet JL, Lasseur C, Combe C,. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet. J Am Soc Nephrol. 2000; 11 (4): 708-716.
46. Jamei M, Dickinson GL, Rostami-Hodjegan A,. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of "bottom-up" vs "top-down" recognition of covariates. Drug Metab Pharmacokinet. 2009; 24: 53-75.
47. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D,. Oxidative metabolism of clarithromycin in the presence of human liver microsomes: major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos. 1997; 25: 632-630.
48. Chu SY, Sennello LT, Bunnell ST, Varga LL, Wilson DS, Sonders RC,. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother. 1992; 26 (11): 2447-2453.
49. Davey PG,. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect. 1991; 19 (suppl A): 29-37.
50. Yago K, Kuroyama M, Motohashi S, Kumano K,. Protein binding of clarithromycin in patients with chronic renal failure. Jpn J Antibiot. 1996; 49 (3): 256-263.
51. Nozinic D, Milic A, Mikac L, Ralic J, Padovan J, Antolovic R,. Assessment of macrolide transport using PAMP, caco-2, and MDCKII-hMDR1 assays. Croatica Chemica Acta. 2010; 83 (3): 323-331.
52. Rodvold KA,. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999; 37 (5): 385-398.
53. Shi J, Chapel S, Montay G, Hardy P, Barrett JS, Sica D, Swan SK, Noveck R, Leroy B, Bhargava VO,. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther. 2005; 43 (3): 123-133.
54. Nolin TD, Himmelfarb J,. Mechanisms of drug-induced nephrotoxicity. Handb Exp Pharmacol. 2010; 196: 111-130.
55. Choudhury C, Ahmed Z,. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006; 2: 80-91.
56. Loghman-Adham M, Kiu Weber, Ciorciaro CI, Mann C, Meier J,. Detection and management of nephrotoxicity during drug development. Exp Opin Drug Saf. 2012; 11: 581-596.
57. Perazella MA,. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009; 4: 1275-1283.
58. Tiong HY, Huang P, Xiong S, Li Y, Vathsala A, Zink D,. Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Mol Pharmaceutics. 2014; 11: 1933-1948.
59. Goodsaid FM, Blank M, Dieterle F, et al., Novel biomarkers of acute kidney toxicity. Clin Pharmacol Ther. 2009; 86: 490-496.
60. Fuchs TC, Hewitt P,. Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. AAPS J. 2011; 13: 615-631.
61. van Meer L, Moerland M, Cohen AF, Burggraaf J,. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. Br J Clin Pharmacol. 2014; 77: 947-957.
62. Dieterle F, Sistare F, Goodsaid F, et al., Renal biomarker qualification submission: a dialogue between the FDA-EMA and Predictive Safety Consortium. Nat Biotechnol. 2010; 28: 455-462.